Table 2 Pooled prevalence of MTBC genotypes in each studied genotype in PTB and EPTB samples

L1

EAI

(16), 1.17%

(799), 12.95%

(7.58–19.47)%

935, 97.75%

< 0.001

0.061

0.192

MANU

(3), 0.74%

(116), 5.41%

(3.03–8.43)%

105, 89.58%

< 0.001

0.06

0.17

L2

Beijing

(52), 2.52%

(481), 8.06%

(5.96–10.44)%

305, 90.52%

< 0.001

0.14

0.27

L3

CAS

(23), 1.21%

(1761), 19.21%

(14.95–23.86)%

1016, 95.97%

< 0.001

0.11

0.16

L4

NEW1

(7), 0.8%

(568), 21.94%

(16.41–28.05)%

263, 90.89

< 0.001

0.09

0.31

T

(10), 0.59%

(1006), 12.16%

(9.18–15.50)%

367, 92.65%

< 0.001

0.089

0.216

Haarlem

(13), 0.67%

(989), 10.38%

(6.62–14.87)%

909, 96.59%

< 0.001

0.054

0.116

Uganda

0%

(60), 9.04%

(3.06–17.74)%

53, 88.87%

< 0.001

0.24

0.64

S

0%

(19) 6.24%

(3.83–9.53)%

6, 53.57%

0.091

0.415

0.817

LAM

(1), 0.31%

(89), 3.59%

(1.85–5.86)%

119, 89.08%

< 0.001

0.052

0.095

URAL

0%

(27), 3.39%

(2.28–4.82)%

8.49, 5.83%

0.386

0.612

0.768

EASTMED

0%

(8), 3.12%

(1.43–5.84)%

2, 0%

0.393

0.78

0.81

X

0%

(46), 2.03%

(0.88–3.64)%

55, 83.76%

< 0.001

0.153

0.319

H37Rv

0%

(11), 1.78%

(0.94–3.05)%

5, 1.99%

0.403

0.419

0.778

TUR

0%

(6), 1.64%

(0.68–3.29)%

1.91, 0%

0.59

0.419

0.654

Cameroon

0%

(7), 1.64%

(0.73–3.15)%

1.61, 0%

0.656

0.69

0.78

L5/6

West African

0%

(4), 0.38%

(0.13–0.87)%

1.9, 0%

0.586

0.513

0.813

Bovis

0%

(45), 3.29%

(1.31–6.13)%

45, 84.73%

< 0.001

0.112

0.278

U

(4), 0.53%

(66), 3.55%

(2.13–5.31)%

28, 72.14%

< 0.001

0.09

0.26